Compare Corsair Gaming Inc (CRSR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs Recursion Pharmaceuticals Inc — how do they compare? Corsair Gaming Inc trades at $12.95 (market cap $1.39B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CRSR | RXRX | |
|---|---|---|
Market Cap | $1.39B | $1.81B |
Sector | Technology | Health |
52-Week High | $14.35 | $6.79 |
52-Week Low | $4.58 | $2.84 |
Enterprise Value | $1.38B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.71, down 4.46% today, but maintains a bullish technical outlook with strong moving average signals. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.23 significantly exceeding the $0.07 estimate. Recent acquisitions and AI product launches, including the Trak Racer asset purchase and Stream Deck AI integration, highlight strategic growth initiatives. However, the stock faces valuation concerns with a P/E ratio of 41.39 and negative net income in 2025.
The outlook remains cautiously optimistic with improving profitability projected for 2026 (2.53% net margin) and strong analyst support (36% buy ratings). Key risks include competitive pressures in gaming hardware and inconsistent cash flow generation. The current price sits near key support at $13, with upside potential to the $15 consensus target if execution continues.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
